Who Benefits From 5 Years of Extended Endocrine Therapy?

MammaPrint genomic testing suggests that only patients with low-risk, not ultra-low-risk or high-risk, breast cancer benefit from 5 years of extended endocrine therapy.
Medscape Medical News

source https://www.medscape.com/viewarticle/986024?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost